Omeros Addiction Program Wins NIH Grant

Xconomy Seattle — 

Seattle-based Omeros (NASDAQ: OMER) said today that the National Institutes of Health has provided a four-year, $3.6 million grant to support mid-stage clinical trials of the company’s experimental anti-addiction drugs. The trials will examine whether the new drugs can help people suffering from addiction to opioid-based painkillers, nicotine, and alcohol, as well as compulsive behaviors like eating disorders. The trials will be conducted at the New York State Psychiatric Institute.  This is the second NIH grant the company’s anti-addiction program has received this year, Omeros said.